SCHEMBL28908019

SCHEMBL28908019

O=[N+]([O-])c1ccc(OC2CCCCC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.48
MAPT P10636 7/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
ALOX12 P18054 1/20 0.47
CYP19A1 P11511 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PTGES O14684 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
PTGS1 P23219 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTGS2 P35354 1/20 0.45
PABPC1 P11940 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749145 0.98 HSPB1 (0.49) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL3882524 0.95 HSPB1 (0.49) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL30114540 0.92 HSPB1 (0.51) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL737467 0.85 HSPB1 (0.46) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL15884404 0.85 ALDH1A1 (0.49) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL30748818 0.85 ALDH1A1 (0.49) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL4713180 0.85 HSPB1 (0.46) HSPB1MAPTALDH1A1LMNANPSR1
SCHEMBL4713179 0.85 HSPB1 (0.46) HSPB1MAPTALDH1A1LMNANPSR1
Hydrochloric Acid SCHEMBL17451217 0.84 HSPB1 (0.45) HSPB1MAPTALDH1A1LMNANPSR1
Hydrochloric Acid SCHEMBL5358947 0.84 HSPB1 (0.45) HSPB1MAPTALDH1A1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
CN-115433121-B Synthetic method of aliphatic diamine monomer for preparing transparent polyimide 东南大学 2023-11-28 CN disclosed
CN-115433121-A Synthetic method of aliphatic diamine monomer for preparing transparent polyimide 东南大学 2022-12-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT HSPB1 2560/4885MAPT 3029/4885ALDH1A1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.